Hematologic Cancer: EXTEND Biomarker Study
Chimeric antigen receptor (CAR)-T cell therapy was approved by the Food and Drug Administration to treat two main types of patients with hematologic malignancies: pediatric and young adults with B cell acute leukemia (B-ALL) and adults with aggressive non-Hodgkin lymphoma (NHL). The goal of the Exploring T cell Engagers to Treat Disease (EXTEND) Study is to identify predictors of response and toxicities in chimeric antigen receptor T cell (CAR-T) therapy.
The EXTEND Study is designed to collect and analyze biospecimens from patients receiving CAR-T cell therapy at a series of points to discover biomarkers and develop clinical diagnostics, including prediction and monitoring of clinical response and toxicities. Information gained from this study will also inform future development of strategies for management of toxicity and rationale for patient-centered selection of subsequent therapy in the event of relapse.
The study enrolled Mayo Clinic patients actively scheduled to receive CAR-T treatment as part of their clinical care. Patients who participated in the EXTEND Study were asked to provide blood samples at various times throughout the course of treatment.
Contact the Center for Individualized Medicine for information on clinical studies and trials.